• WKN: A2AR94
  • ISIN: NL0012044747
  • Land: Niederlande

Nachricht vom 06.07.2021 | 07:30

SHOP APOTHEKE EUROPE: Growth in Q2 temporarily decelerated to 7.3%. Preliminary sales grew by 14.9% during the first six months of 2021.

DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Preliminary Results/Development of Sales
06.07.2021 / 07:30
The issuer is solely responsible for the content of this announcement.

SHOP APOTHEKE EUROPE: Growth in Q2 temporarily decelerated to 7.3%. Preliminary sales grew by 14.9% during the first six months of 2021.

  • Temporarily reduced logistics capacity due to the ongoing move to the new facility and a tight labour market in Q2.
  • Full-year 2021 guidance of growing around 20% and earnings guidance on adjusted EBITDA margin of 2.3 - 2.8% has become challenging.
  • Strong customer demand continued in all of countries.
  • SHOP APOTHEKE EUROPE is ready for e-Rx and Gematik started the roll-out in a test environment last week.
  • Strong progress on strategic initiatives: Same-day delivery service SHOP APOTHEKE NOW! is available in all major German metropolitan areas ahead of schedule.

Sevenum, 6 July 2021. SHOP APOTHEKE EUROPE, active in seven European countries, has increased sales for H1 2021 by 14.9% to EUR 534 million. On a quarterly basis, sales rose by 7.3% to EUR 250 million. The number of active customers increased in Q2 alone by 0.3 million to well above 7 million.

CEO Stefan Feltens: "The execution of our strategic initiatives as well as customer demand in all countries we serve continued to develop strongly in Q2. The testing period for e-Rx in Germany has gone live as scheduled on 1 July 2021, and our same-day delivery service SHOP APOTHEKE NOW! is already available to more than 20 million people in 13 metropolitan areas across Germany including Berlin, Hamburg and Munich. However, we had to slow down our growth this quarter, which will impact our earnings in Q2. Staff numbers failed to maintain pace to fully cope with increasing customer demand both in Q2 and at the start of Q3. Additionally, the ramp-up to the next level of automation takes more time than we aimed for and temporarily operating two logistics facilities in parallel is complex."

In the DACH segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE's Q2 sales grew by 3.8% to EUR 198 million compared to previous year's 190 million. H1 sales increased by 9.5% to EUR 428 million after EUR 391 million in 2020. Declining Rx sales were offset by double digit growth in the non-Rx categories.

In the International segment (Belgium, France, Italy, the Netherlands), SHOP APOTHEKE EUROPE increased its sales in the second quarter of 2021 by 23.0% to EUR 52 million compared to EUR 42 million in Q2 2020. H1 sales increased by 43.4% to EUR 105 million after EUR 74 million in 2020.

For the full-year 2021, the Management Board of SHOP APOTHEKE EUROPE has an earnings guidance of organically driven sales growth of around 20% or more and an adjusted EBITDA margin in the range of a positive 2.3% - 2.8% (2020: 2.2%). This guidance for 2021 has become challenging due to the current lower than anticipated logistics capacity; whether an update will be needed depends on the developments of the coming weeks.

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE N.V. will release the full interim report for the second quarter of 2021 on 5 August 2021. Definitions of non-IFRS terms can be found in the Glossary of the Annual Report 2020 (pages 146 and 147).


SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Warsaw, Milan, Paris and Tongeren, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, more than 7 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany in summer 2021, the company will further improve the customer experience with focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and has been part of the MDAX stock index since September 2020.


Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31

Financial media:
Bettina Fries
Tel: +49 211 75 80 779

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109

Thomas Schnorrenberg
Mobile: +49 151 465 31317

06.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Vonovia verkauft Berliner Wohnungsbestände aus dem Zukunfts- und Sozialpakt Wohnen

17. September 2021, 12:40

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

CR Capital AG

Original-Research: CR Capital AG (von First Berlin Equity Research GmbH): Buy

17. September 2021